1. Adams, M., Thomas, H., 1998, A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapse ovarian cancer. Proc.Am.Soc.Clin.Oncol. 17:217 (abstract 838).
2. Airola, K., Karonen, T., Vaalamo, M., Lehti, K., Lohi, J., Kariniemi, A.L., Keski-Oja, J., Saarialho-Kere, U.K., 1999, Expression of collagenases-1 and-3 and their inhibitors TIMP-1 and-3 correlates with the level of invasion in malignant melanomas. Br.J.Cancer 80:733–743.
3. Ahmann, F.R., Saad, F., Mercier, R., et al., 2001, Interim Results of a Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat in Patients Having Metastatic, Hormone Refractory Prostate Cancer (HRPC). Proc. ASCO. 20:692 (abstract).
4. Ahonen, M., Baker, A.H., Kahari, V.M., 1998, Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3 inhibits invasion and inducec apoptosis in melanoma cells. Cancer Res. 58:2310–2315.
5. Anand-Apte, B., Pepper, M., Voest, E., Montesano, R., Olsen, B., Murphy, G., 1997, lnibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest.Opthamol. Vis. Sci. 38:817–823.